Given that the expression of the COX-IS was strongly driven by oncogenic KRAS signaling in both mouse and human lung cancer, our studies suggest that inhibiting the COX2/PGE2 axis is a promising therapeutic strategy in KRAS-mutant non–small cell lung cancer and may broaden the efficacy of ICB for these patients. The gene discussed is KRAS; the disease is lung cancer.